Literature DB >> 10682143

Opportunistic infections shortly after beginning highly active antiretroviral therapy.

R Rodríguez-Rosado1, V Soriano, C Dona, J González-Lahoz.   

Abstract

The clinical benefit of highly active antiretroviral therapy (HAART) has been attributed to its suppression of viral replication and improvement in the CD4 lymphocyte count. However, the development of clinical symptoms secondary to previously silent opportunistic pathogens shortly after beginning HAART has been reported as a distinct clinical syndrome and seems to be associated with inflammatory phenomena surrounding a rapid restoration of the immune system in previously immunosuppressed patients. Herein, we report nine (3.6%) episodes of opportunistic infections (OI) in 247 human immunodeficiency virus (HIV)-infected patients undergoing HAART in a reference HIV/AIDS institution located in Madrid, Spain. In all instances, OI clustered within the first 3 months after beginning HAART. Episodes of cerebral toxoplasmosis (three cases), Pneumocystis carinii pneumonia (two cases), and herpes zoster (two cases) occurred in persons without a previous AIDS-defining illness, in addition a relapse of cytomegalovirus retinitis and a rebound in Kaposi's sarcoma were seen, respectively, in another two patients. Four of the nine subjects had a CD4 count above 200 cells/mm3 before HAART began. Of these, one developed Pneumocystis pneumonia and one other cerebral toxoplasmosis. In conclusion, prophylaxis and close clinical monitoring of HIV-infected patients should be considered for the first 3 months after beginning HAART, even for subjects without severe immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10682143

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  6 in total

1.  The management of Pneumocystis carinii pneumonia.

Authors:  F J Vilar; S H Khoo; T Walley
Journal:  Br J Clin Pharmacol       Date:  1999-06       Impact factor: 4.335

2.  Immune Reconstitution and the Consequences for Opportunistic Infection Treatment and Prevention.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

3.  In vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase.

Authors:  M G Reynolds; J Oh; D S Roos
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 4.  CNS-immune reconstitution inflammatory syndrome in the setting of HIV infection, part 2: discussion of neuro-immune reconstitution inflammatory syndrome with and without other pathogens.

Authors:  M J D Post; M M Thurnher; D B Clifford; A Nath; R G Gonzalez; R K Gupta; K K Post
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-12       Impact factor: 3.825

Review 5.  Parasitic infections in HIV infected individuals: diagnostic & therapeutic challenges.

Authors:  Veeranoot Nissapatorn; Nongyao Sawangjaroen
Journal:  Indian J Med Res       Date:  2011-12       Impact factor: 2.375

6.  Effects of highly active antiretroviral therapy and its adherence on herpes zoster incidence: a longitudinal cohort study.

Authors:  Chenglong Liu; Cuiwei Wang; Marshall J Glesby; Gypsyamber D'souza; Audrey French; Howard Minkoff; Toby Maurer; Roksana Karim; Mary Young
Journal:  AIDS Res Ther       Date:  2013-12-27       Impact factor: 2.250

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.